Amanta Healthcare IPO GMP Jumps 20% as Issue Oversubscribed 327% on Day 1; Is it Worth A Bet?

Amanta Healthcare IPO GMP is currently soaring above 22% after it opened for subscription today, September 1, 2025, and is seeing a good response on its first day. By 2:44 PM, the issue was subscribed 3.27 or 327% times overall with strong participation from retail & institutional investors.

According to NSE data, the Amanta Healthcare IPO retail category was subscribed 4.93 times, while the non-institutional investor (NII) portion saw 3.74 times subscription. However, the Qualified Institutional Buyers (QIB) category recorded no subscription so far on Day 1, excluding anchor investors.

Amanta Healthcare IPO Details

The Amanta Healthcare IPO is worth Rs. 126 crore, consisting entirely of a fresh issue of 1 crore equity shares. The IPO is open for subscription from Sep 1st to Sep 3rd. The company has fixed the IPO price band at Rs. 120 to 126 per share.

Amanta Healthcare IPO share allotment will be conducted on September 4th, and the tentative listing is expected on Sept 9th.

Amanta Healthcare IPO GMP

The GMP trend will play a major role in indicating potential listing gains ahead of the IPO's debut. As of 2:30 pm, the last recorded Amanta Healthcare IPO GMP stood at Rs 25 per share. Given the price of Rs. 126, the IPO coil list is at Rs. 151. Which means 19.85% profit for investors.

Should You Subscribe?

According to Exential Research Partners, "We recommend 'subscribe for long-term gains'. While valuations appear rich, Amanta Healthcare offers a differentiated play on India's growing sterile injectables and IV fluids market. Its established manufacturing expertise, strong domestic and export footprint, and capacity expansion plans provide growth visibility. Conservative investors may wait, but long-term players can consider exposure for gradual wealth creation."

About Amanta Healthcare

Founded in December 1994, Ahmedabad-based Amanta Healthcare Limited is a dynamic pharmaceutical firm specialising in the development, manufacturing, and marketing of sterile liquid pharmaceuticals and medical devices.The company's core product offerings include large and small volume parenterals (LVPs & SVPs), such as IV fluids, diluents, ophthalmic solutions, respiratory care products, irrigation solutions, eye lubricants, and first-aid items.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.